Prognostic Factors for Survival in Patients With High-grade Chondrosarcoma

Cancer Diagn Progn. 2022 Nov 3;2(6):681-685. doi: 10.21873/cdp.10159. eCollection 2022 Nov-Dec.

Abstract

Background/aim: Chondrosarcoma (CS) is a rare primary malignant bone tumor, which is the second most common tumor after osteosarcoma. Since chemotherapy and radiotherapy have poor efficacy for CS, amputation or surgical wide resection is the main strategy for localized high-grade CS, making CS therapy difficult. As studies on high-grade CS are limited owing to its rare nature, there are many unknown prognostic factors for survival.

Patients and methods: This retrospective cohort study included 44 patients with high-grade CS who underwent surgery at a single institution. Overall survival (OS), distant failure-free survival (DFFS), and local failure-free survival (LFFS) were evaluated using the Kaplan-Meier method. Furthermore, we evaluated prognostic factors for survival in patients with high-grade CS using univariate and multivariate analyses.

Results: The 5-year OS, LFFS, and DFFS rates of high-grade CS were 75.9%, 90.8%, and 66.5%, respectively. Univariate analysis revealed that tumor size, tumor grade, and surgical margin were significant prognostic factors for OS and DFFS, and distant metastasis was significantly associated with OS. Furthermore, the multivariate analysis indicated that the presence of local recurrence and distant metastasis was significantly associated with OS.

Conclusion: Local recurrence and distant metastasis were significant prognostic factors for high-grade CS.

Keywords: Chondrosarcoma; distant metastasis; local recurrence; overall survival; prognostic factor.